Xeris Biopharma (XERS) director logs stock sale and new equity grants
Rhea-AI Filing Summary
Xeris Biopharma Holdings director Marla Persky reported both equity awards and a share sale. On June 4, 2026, she received 24,193 shares of Common Stock via a restricted stock unit grant that vests in full on the earlier of June 4, 2026 or the company’s next annual stockholders meeting, subject to continued service.
She also received 32,996 stock options with an exercise price of $6.15 per share, vesting on the same schedule and expiring on June 4, 2036. A day earlier, on June 3, 2026, she sold 15,500 shares of Common Stock in open-market transactions at a weighted average price of $5.8989 per share under a pre-arranged Rule 10b5-1 trading plan, leaving 150,693 shares held directly after the awards. The filing also shows 6,370 shares held indirectly through the Marla Susan Persky Revocable Trust, with beneficial ownership disclaimed except to the extent of pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Buyer: 8,693 shares
Net Buy
4 txns
Insider
PERSKY MARLA
Role
Director
Sold
15,500 shs ($91K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,996 | $6.15 | $203K |
| Grant/Award | Common Stock | 24,193 | $0.00 | $0.00 |
| Sale | Common Stock | 15,500 | $5.8989 | $91K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,996 shares (Direct);
Common Stock — 150,693 shares (Direct);
Common Stock — 6,370 shares (Indirect, By: Marla Susan Persky Revocable Trust u/a dated 9/23/2000)
Footnotes (5)
- F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.810 to $5.960, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
- F4. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F5. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Key Figures
RSU Grant: 24,193 shares
Option Grant: 32,996 options at $6.15
Shares Sold: 15,500 shares at $5.8989
+2 more
5 metrics
RSU Grant
24,193 shares
Restricted stock unit grant of Common Stock on June 4, 2026
Option Grant
32,996 options at $6.15
Stock options to buy Common Stock, expire June 4, 2036
Shares Sold
15,500 shares at $5.8989
Open-market sale of Common Stock on June 3, 2026
Direct Holdings After
150,693 shares
Common Stock held directly following reported transactions
Indirect Trust Holdings
6,370 shares
Common Stock held by Marla Susan Persky Revocable Trust
Key Terms
Rule 10b5-1 trading plan, restricted stock unit, 2018 Stock Option and Incentive Plan, pecuniary interest, +1 more
5 terms
Rule 10b5-1 trading plan financial
"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock unit financial
"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
2018 Stock Option and Incentive Plan financial
"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"
pecuniary interest financial
"The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
revocable trust financial
"By: Marla Susan Persky Revocable Trust u/a dated 9/23/2000"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Xeris Biopharma (XERS) director Marla Persky report?
Marla Persky reported a mix of transactions: open-market sales of 15,500 Xeris Biopharma shares and grants of 24,193 restricted stock units plus 32,996 stock options, all recorded in a single Form 4 filing.
What equity awards did Marla Persky receive from Xeris Biopharma (XERS)?
She received 24,193 shares through a restricted stock unit grant and 32,996 stock options with a $6.15 exercise price. Both awards vest in full on the earlier of June 4, 2026 or Xeris Biopharma’s next annual stockholders meeting.
When do Marla Persky’s new Xeris Biopharma stock awards vest?
Both the 24,193-share restricted stock unit award and the 32,996-share stock option grant vest in full upon the earlier of June 4, 2026 or the date of Xeris Biopharma’s next annual meeting of stockholders, assuming continued service through that date.
Did Marla Persky’s Xeris Biopharma (XERS) stock sale follow a Rule 10b5-1 plan?
Yes. The filing states the 15,500-share sale was executed under a Rule 10b5-1 trading plan. That plan was adopted on June 12, 2025, indicating the trades were pre-arranged rather than discretionary market-timing decisions.